Preview

Современная ревматология

Расширенный поиск

Вакцинация в ревматологии: современность и перспективы

https://doi.org/10.14412/1996-7012-2012-740

Полный текст:

Аннотация

В современной ревматологии коморбидные инфекции (КИ) оказывают значительное влияние на морбидность и летальность, особенно при системных болезнях соединительной ткани. В связи с этим большое внимание уделяется активному внедрению в ревматологическую практику различных вакцин. Многочисленные данные свидетельствуют об отсутствии негативного влияния иммунизации на течение основного ревматического заболевания (РЗ). Продемонстрированы эффективность и безопасность вакцинации, направленной на предупреждение инфекций дыхательных путей как наиболее значимых КИ при РЗ. Представлены основные положения рекомендаций EULAR по вакцинации у больных РЗ, а также ключевые направления будущих исследований по данной проблеме.

Литература

1. <div><p>Белов Б.С., Балабанова Р.М., Манукян С.Г. и др. Коморбидные инфекции при ревматических заболеваниях. Тез. докл. междунар. конф. ревматол. Чимкент, 2006; 17.</p><p>Wolfe F., Mitchell D.M., Sibley J.T. The mortality of rheumatoid arthritis. Arthr Rheum 1994; 37(4): 481—94.</p><p>Сороцкая В.Н. Распространенность и причины летальных исходов ревматических заболеваний на модели Тульской области. Автореф. дисс.. докт. мед. наук. Тула, 2005; 48 с.</p><p>Zonana-Nacach A., Camargo-Coronel A., Yanez P. et al. Infections in outpatients with systemic lupus erythematosus: a prospective study. Lupus 2001; 10(7): 505—10.</p><p>Khalifa M., Kaabia N., Bahri F. et al. Infection in systemic lupus erythematosus. Med Mal Infect 2007; 37(12): 792—5.</p><p>Wallace D.J., Podell T., Weiner J. et al. Systemic lupus erythematosus—survival patterns. Experience with 609 patients. JAMA 1981; 245(9): 934—8.</p><p>Rosner S., Ginzler E.M., Diamond H.S. et al. A multicenter study of outcome in systemic lupus erythematosus. II. Causes of death. Arthr Rheum 1982; 25(6): 612—7.</p><p>Helve T. Prevalence and mortality rates of systemic lupus erythematosus and causes of death in SLE patients in Finland. Scand J Rheum 1985; 14(1): 43—6.</p><p>Ward M.M., Pyun E., Studenski S. Longterm survival in systemic lupus erythematosus. Patient characteristics associated with poorer outcomes. Arthr Rheum 1995; 38(2): 274—83.</p><p>Лучихина Е.Л. Анализ структуры летальных исходов при системной красной волчанке: Автореф. дисс.. канд. мед. наук. М., 1998; 24 с.</p><p>Nossent J., Cikes N., Kiss E. et al. Current causes of death in systemic lupus erythematosus in Europe, 2000—2004: relation to disease activity and damage accrual. Lupus 2007; 16(5): 309—17.</p><p>Edwards C.J., Lian T.Y., Badsha H. et al. Hospitalization of individuals with systemic lupus erythematosus: characteristics and predictors of outcome. Lupus 2003; 12(9): 672—6.</p><p>Martin-Suarez I., D’Cruz D., Mansoor M. et al. Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide. Ann Rheum Dis 1997; 56: 481—7.</p><p>Gladman D.D., Hussain F., Iban D. et al. The nature and outcome of infection in systemic lupus erythematosus. Lupus 2002; 11: 234—9.</p><p>Kroesen S., Widmer A.F., Tyndall A. et al. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-α therapy. Rheumatology 2003; 42: 617—21.</p><p>Gluck T., Kiefmann B., Grohmann M. et al. Immune status and risk for infection in patients receiving chronic immunosuppressive therapy. J Rheum 2005; 32(8): 1473—80.</p><p>Ng W.L., Chu C.M., Wu A.K.L. et al. Lymphopenia at presentation is associated with increased risk of infections in patients with systemic lupus erythematosus. Q J Med 2006; 99: 37—47.</p><p>Reddy S., Wanchu A., Gupta V. et al. Profile of opportunistic infections among patients on immunosuppressive medication. APLAR J Rheum 2006; 9: 269—74.</p><p>Bernatsky S., Hudson M., Suissa S. Antirheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumarology 2007; 46: 1157—60.</p><p>Franklin J., Lunt M., Bunn D. et al. Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis. Ann Rheum Dis 2007; 66: 308—12.</p><p>Smitten A.L., Choi H.K., Hochberg M.C. et al. The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheum 2008; 35(3): 387—93.</p><p>Coyne P., Hamilton J., Heycock C. et al. Acute lower respiratory tract infections in patients with rheumatoid arthritis. J Rheum 2007; 34(9): 1832—6.</p><p>Huskisson E.C., Hart F.D. Severe, unusual and recurrent infections in rheumatoid arthritis. Ann Rheum Dis 1972; 31: 118—21.</p><p>Doran M.F., Crowson C.S., Pond G.R. et al. Frequency of infection in patients with rheumatoid arthritis compared with controls. Arthr Rheum 2002; 46(9): 2287—93.</p><p>Полянская М.В. Пневмония у пациентов с ревматическими заболеваниями: частота встречаемости, клиническая картина, факторы риска. Автореф. дисс.. канд. мед. наук. М., 2009; 24 с.</p><p>Noel V., Lortholary O., Casassus P. et al. Risk factors and prognostic influence of infection in a single cohort of 87 adults with systemic lupus erythematosus. Ann Rheum Dis 2001; 60(12): 1141 —4.</p><p>Koivuniemi R., Leirisalo-Repo M., Suomalainen R. et al. Infectious causes of death in patients with rheumatoid arthritis: an autopsy study. Scand J Rheum 2006; 35: 273—6.</p><p>Housden M.M., Bell G., Heycock C.R. et al. How to reduce morbidity and mortality from chest infections in rheumatoid arthritis. Clin Med 2010; 10(4): 326—9.</p><p>Juarez M., Misischia R., Alarcon G.A. Infections in systemic connective tissue diseases: systemic lupus erythematosus, scleroderma, and polymyositis/dermatomyositis. Rheum Dis Clin N Am 2003; 29: 163—84.</p><p>Moss K.E., Ioannou Y., Sultan S.M. et al. Outcome of a cohort of 300 patients with systemic lupus erythematosus attending a dedicated clinic for over two decades. Ann Rheum Dis 2002; 61: 409—13.</p><p>Narata R., Wangkaew S., Kasitanon N. et al. Community-acquired pneumonia in Thai patients with systemic lupus erythematosus. Southeast Asian J Trop Med Public Health 2007; 38(3): 528—36.</p><p>Curtis J.R., Patkar N., Xie A. et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthr Rheum 2007; 56(4): 1125—33.</p><p>Askling J., Fored C.M., Brandt L. et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 2007; 66(10): 1339—44.</p><p>Lane M.A., McDonald J.R., Zeringue A.L. et al. TNF-α antagonist use and risk of hospitalization for infection in a national cohort of veterans with rheumatoid arthritis. Medicine (Baltimore) 2011; 90(2): 139—45.</p><p>Salliot C., Gossec L., Ruyssen-Witrand A. et al. Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. Rheumatology 2007; 46(2): 327—34.</p><p>Gottenberg J.E., Ravaud P., Bardin T. et al.; AutoImmunity and Rituximab registry and French Society of Rheumatology. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthr Rheum 2010; 62(9): 2625—32.</p><p>Van Vollenhoven R.F., Emery P., Bingham C.O. 3rd et al. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheum 2010; 37(3): 558—67.</p><p>Koike T., Harigai M., Inokuma S. et al. Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients. Ann Rheum Dis 2011; 70(12): 2148—51.</p><p>Kremer J.M., Genant H.K., Moreland L.W. et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Int Med 2006; 144(12): 865—76.</p><p>Schiff M., Pritchard C., Huffstutter J.E. et al. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after antitumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. Ann Rheum Dis 2009; 68(11): 1708—14.</p><p>Lanternier F., Henegar C., Mouthon L. et al. Low influenza-vaccination rate among adults receiving immunosuppressive therapy for systemic inflammatory disease. Ann Rheum Dis 2008; 67(7): 1047.</p><p>Pradeep J., Watts R., Clunie G. Audit on the uptake of influenza and pneumococcal vaccination in patients with rheumatoid arthritis. Ann Rheum Dis 2007; 66(6): 837—8.</p><p>Медуницын Н.В. Вакцинология. М.: Триада-Х, 2004; 448 с.</p><p>Kuroda Y., Nacionales D.C., Akaogi J. et al. Autoimmunity induced by adjuvant hydrocarbon oil components of vaccine. Biomed Pharmacother 2004; 58(5): 325—37.</p><p>Bach J.F. Protective role of infections and vaccinations on autoimmune diseases. J Autoimmun 2001; 16(3): 347—53.</p><p>Levitsky L.L. Childhood immunizations and chronic illness. N Engl J Med 2004; 350(14): 1380—2.</p><p>Williams G.W., Steinberg A.D., Reinertsen J.L. et al. Influenza immunization in systemic lupus eruthematosus. A doubleblind trial. Ann Int Med 1978; 88(6): 729—34.</p><p>Brodman R., Gilfillan R., Glass D. et al. Influenzal vaccine response in systemic lupus erythematosus. Ann Int Med 1978; 88(6): 735—40.</p><p>Louie J.S., Nies K.M., Shoji K.T. et al. Clinical and antibody responses after influenza immunization in systemic lupus erythematosus. Ann Int Med 1978; 88(6): 790—2.</p><p>Ristow S.C., Douglas R.G.Jr, Condemi J.J. Influenza vaccination of patients with systemic lupus erythematosus. Ann Int Med 1978; 88(6): 786—9.</p><p>Herron A., Dettleff G., Hixon B. et al. Influenza vaccination in patients with rheumatic diseases. Safety and efficacy. JAMA 1979; 242(1): 53—6.</p><p>Abu-Shakra M., Zalmanson S., Neumann L. et al. Influenza virus vaccination of patients with systemic lupus erythematosus: effects on disease activity. J Rheum 2000; 27(7): 1681—5.</p><p>Abu-Shakra M., Press J., Sukenik S. et al. Influenza virus vaccination of patients with SLE: effects on generation of autoantibodies. Clin Rheum 2002; 21(5): 369—72.</p><p>Abu-Shakra M., Press J., Varsano N. et al. Specific antibody response after influenza immunization in systemic lupus erythematosus. J Rheum 2002; 29(12): 2555—7.</p><p>Holvast A., van Assen S., de Haan A. et al. Studies of cell-mediated immune responses to influenza vaccination in systemic lupus erythematosus. Arthr Rheum 2009; 60(8): 2438—47.</p><p>Holvast A., van Assen S., de Haan A. et al. Effect of a second, booster, influenza vaccination on antibody responses in quiescent systemic lupus erythematosus: an open, prospective, controlled study. Rheumatology 2009; 48(10): 1294—9.</p><p>Mathian A., Devilliers H., Krivine A. et al. Factors influencing the efficacy of two injections of a pandemic 2009 influenza A (H1N1) nonadjuvanted vaccine in systemic lupus erythematosus. Arthr Rheum 2011; 63(11): 3502—11.</p><p>Crowe S.R., Merrill J.T., Vista E.S. et al. Influenza vaccination responses in human systemic lupus erythematosus: impact of clinical and demographic features. Arthr Rheum 2011; 63(8): 2396—406.</p><p>Battafarano D.F., Battafarano N.J., Larsen L. et al. Antigen-specific antibody responses in lupus patients following immunization. Arthr Rheum 1998; 41(10): 1828—34.</p><p>Elkayam O., Paran D., Burke M. et al. Pneumococcal vaccination of patients with systemic lupus erythematosus: effects on generation of autoantibodies. Autoimmunity 2005; 38(7): 493—6.</p><p>Mercado U. Why have rheumatologists been reluctant to vaccinate patients with systemic lupus erythematosus? J Rheum 2006; 33(8): 1469—71.</p><p>Bengtsson C., Kapetanovic M.C., Källberg H. et al.; EIRA Study Group. Common vaccinations among adults do not increase the risk of developing rheumatoid arthritis: results from the Swedish EIRA study. Ann Rheum Dis 2010; 69(10): 1831—3.</p><p>Chalmers A., Scheifele D., Patterson C. et al. Immunization of patients with rheumatoid arthritis against influenza: a study of vaccine safety and immunogenicity. J Rheum 1994; 21(7): 1203—6.</p><p>Del Porto F., Lagana B., Biselli R. et al. Influenza vaccine administration in patients with systemic lupus erythematosus and rheumatoid arthritis. Safety and immunogenicity. Vaccine 2006; 24(16): 3217—23.</p><p>Stojanovich L. Influenza vaccination of patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Clin Dev Immunol 2006; 13(2—4): 373—5.</p><p>Elkayam O., Bashkin A., Mandelboim M. et al. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthr Rheum 2010; 39(6): 442—7.</p><p>Fomin I., Caspi D., Levy V. et al. Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers. Ann Rheum Dis 2006; 65(2): 191—4.</p><p>Kaine J.L., Kivitz A.J., Birbara C. et al. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheum 2007; 34(2): 272—9.</p><p>Kapetanovic M.C., Saxne T., Sjöholm A. et al. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford) 2006; 45(1): 106—11.</p><p>Kapetanovic M.C., Saxne T., Nilsson J.A. et al. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients. Rheumatology (Oxford) 2007; 46(4): 608—11.</p><p>Coulson E., Saravanan V., Hamilton J. et al. Pneumococcal antibody levels after pneumovax in patients with rheumatoid arthritis on methotrexate. Ann Rheum Dis 2011; 70(7): 1289—91.</p><p>Van Assen S., Holvast A., Benne C.A. et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthr Rheum 2010; 62(1): 75—81.</p><p>Bingham C.O. 3rd, Looney R.J., Deodhar A. et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthr Rheum 2010; 62(1): 64—74.</p><p>Schiff M., Kaell A., Tay L. et al. Response to pneumococcal vaccine in rheumatoid arthritis patients with an inadequate response to anti-TNF therapy treated with abatacept in the arrive trial. Ann Rheum Dis 2007; 66(Suppl. II): 437.</p><p>Pham T., Claudepierre P., Constantin A. et al. Abatacept therapy and safety management. Joint Bone Spine 2009; 76 (Suppl. 1): S3—S55.</p><p>Mori S., Ueki Y., Hirakata N. et al. Impact of tocilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis. Ann Rheum Dis Published online: 11 Aug 2012.</p><p>Pham T., Claudepierre P., Constantin A. et al.; Club Rhumatismes et Inflammation (CRI). Tocilizumab: therapy and safety management. Joint Bone Spine 2010; 77 (Suppl. 1): S3—100.</p><p>Zhang J., Xie F., Delzell E. et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA 2012; 308(1): 43—9.</p><p>Van Assen S., Agmon-Levin N., Elkayam O. et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2011; 70(3): 414—22.</p><p>Kavanaugh A. Infection prophylaxis in antirheumatic therapy: emphasis on vaccination. Curr Opin Rheum 2009; 21(4): 419—24.</p><p>Salemi S., D'Amelio R. Are anti-infectious vaccinations safe and effective in patients with autoimmunity? Int Rev Immunol 2010; 29(3): 270—314.</p><p>Brezinschek H.P., Hofstaetter T., Leeb B.F. et al. Immunization of patients with rheumatoid arthritis with antitumor necrosis factor alpha therapy and methotrexate. Curr Opin Rheumatol 2008; 20(3): 295—9.</p><p>Bijl M., Agmon-Levin N., Dayer J.M. et al. Vaccination of patients with autoimmune inflammatory rheumatic diseases requires careful benefit-risk assessment. Autoimmun Rev 2012; 11(8): 572—6.</p></div><br />


Для цитирования:


Белов Б.С., Тарасова Г.М., Наумцева М.С. Вакцинация в ревматологии: современность и перспективы. Современная ревматология. 2012;6(3):15-22. https://doi.org/10.14412/1996-7012-2012-740

For citation:


Belov B.S., Tarasova G.M., Naumtseva M.S. Vaccination in rheumatology: the present and prospects. Modern Rheumatology Journal. 2012;6(3):15-22. (In Russ.) https://doi.org/10.14412/1996-7012-2012-740

Просмотров: 1354


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1996-7012 (Print)
ISSN 2310-158X (Online)